News Center
News and Information
03-24
Our company’s oxcarbazepine extended-release tablets have been approved for clinical trials.
03-12
Renfulikang Holds “Flourishing Youth, Fragrant Bloom” Care-for-Women Service Event
Renfulikang Holds “Flourishing Youth, Fragrant Bloom” Care-for-Women Service Event
02-17
[Attention] 400 million yuan anti-influenza injection—Renfu aims for the first generic version.
On February 15, Renfu Pharmaceutical issued an announcement stating that the paravir injection developed by its controlling subsidiary, Renfulikang Pharmaceutical, has been accepted by the CDE after being submitted as a Class 3 generic drug application. To date, Renfulikang Pharmaceutical has cumulatively invested approximately 6 million yuan in this project. According to data from Menet, in 2021, sales of paravir injection at the terminal level in China’s public medical institutions exceeded 400 million yuan, and in the first half of 2022, sales grew by more than 50% year-on-year.
Trending News
Corporate culture
Make drug launches safer and faster, and ensure the tree of life remains evergreen.
Learn moreContact Us
Business customer service
-
Telephone：:+86-027-86506632
Human Resources Department
Address: No.98 shendun 2nd Road, Donghu New Technology Development Zone, Wuhan
Official wechat
Copyright: Wuhan humanwell likang pharmaceutical co.,ltd